RAPT Therapeutics, Inc. (RAPT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Brian Russell Wong M.D., Ph.D. | CEO, President & Director | 861.24k | -- | 1972 |
| Mr. Rodney K. B. Young | CFO, Principal Accounting Officer & Secretary | 616.56k | -- | 1963 |
| Dr. William Ho M.D., Ph.D. | Chief Medical Officer | 620.32k | -- | 1966 |
| Steve Young Ph.D. | Vice President of Technology | -- | -- | -- |
| Dr. Dirk G. Brockstedt Ph.D. | Chief Scientific Officer | 490.25k | -- | 1969 |
| Mr. Michael Listgarten | General Counsel | -- | -- | -- |
| Ms. Gwen R. Carscadden | Chief Human Resources Officer | -- | -- | 1961 |
| Dr. Paul Kassner | Senior Vice President of Quantitative & Computational Biology | -- | -- | 1967 |
| Dr. David Wustrow | Senior Vice President of Drug Discovery & Preclinical Development | -- | -- | 1959 |
| Ms. Jennifer Nicholson | Senior Vice President of Regulatory Affairs & Quality Assurance | -- | -- | -- |
RAPT Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 131
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
Corporate Governance
Recent Events
- Apr 05, 2024DEF 14A: Proxy StatementsSee Full Filing
- Mar 07, 2024S-8: Offering RegistrationsSee Full Filing
- Feb 22, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 20, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 14, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing